44 research outputs found
Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy
The effect of deferasirox dosing tailored for iron burden and iron loading based on liver iron concentration (LIC) was assessed over 1 year in less versus more heavily iron-overloaded patients in a substudy of the Evaluation of Patients' Iron Chelation with ExjadeA (R). Deferasirox starting dose was 10-30 mg/kg/day, depending on blood transfusion frequency, with recommended dose adjustments every 3 months. Therapeutic goals were LIC maintenance or reduction in patients with baseline LIC < 7 or a parts per thousand yen7 mg Fe/g dry weight (dw), respectively. Changes in LIC (R2-magnetic resonance imaging) and serum ferritin after 1 year were assessed. Adverse events (AEs) and laboratory parameters were monitored throughout. Of 374 patients, 71 and 303 had baseline LIC < 7 and a parts per thousand yen7 mg Fe/g dw, respectively; mean deferasirox doses were 20.7 and 27.1 mg/kg/day (overall average time to dose increase, 24 weeks). At 1 year, mean LIC and median serum ferritin levels were maintained in the low-iron cohort (-0.02 A +/- 2.4 mg Fe/g dw, -57 ng/mL; P = not significant) and significantly decreased in the high-iron cohort (-6.1 A +/- 9.1 mg Fe/g dw, -830 ng/mL; P < 0.0001). Drug-related gastrointestinal AEs, mostly mild to moderate, were more frequently reported in the < 7 versus a parts per thousand yen7 mg Fe/g dw cohort (39.4 versus 20.8 %; P = 0.001) and were not confounded by diagnosis, dosing, ethnicity, or hepatitis B and/or C history. Reported serum creatinine increases did not increase in low- versus high-iron cohort patients. Deferasirox doses of 20 mg/kg/day maintained LIC < 7 mg Fe/g dw and doses of 30 mg/kg/day were required for net iron reduction in the high-iron cohort, with clinically manageable safety profiles. The higher incidence of gastrointestinal AEs at lower iron burdens requires further investigation
Development of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO©)
\u3b2-Thalassemia, a hereditary blood disorder caused by reduced or absent synthesis of the \u3b2-globin chain of hemoglobin, is characterized by ineffective erythropoiesis, and can manifest as nontransfusion-dependent thalassemia (NTDT) or transfusion-dependent thalassemia (TDT). Many patients with NTDT develop a wide range of serious complications that affect survival and quality of life (QoL). Patient-reported outcomes (PRO), including health-related QoL (HRQoL), are important tools for determining patient health impairment and selecting appropriate treatment. However, there are currently no disease-specific PRO tools available to assess symptoms related to chronic anemia experienced by patients with NTDT. This study aimed to develop a new, US Food and Drug Administration (FDA)-compliant PRO of chronic anemia symptoms, the NTDT-PRO\ua9 tool, for use in patients with NTDT. Participants had a median age of 36 years (range, 18-47) and 60% were female. The initial development of the NTDT-PRO tool involved concept-elicitation interviews with 25 patients from 3 centers (in Lebanon, Greece, and Canada); subsequent interview discussions and clinical input resulted in the generation of 9 items for inclusion in the draft NTDT-PRO. Following a round of cognitive interviews involving 21 patients from 2 centers (in Lebanon and Greece), 4 items (Pain, Headaches, Ability to Concentrate, and Paleness) were removed from the draft NTDT-PRO. The final NTDT-PRO comprises 6 items that measure Tiredness, Weakness, and Shortness of Breath, with or without Physical Activity. The NTDT-PRO is a new disease-specific HRQoL tool for patients with NTDT, developed using a thorough methodology based on FDA 2009 PRO development guidelines
A colorimetric strategy based on dynamic chemistry for direct detection of Trypanosomatid species
Leishmaniasis and Chagas disease are endemic in many countries, and re-emerging in the developed
countries. A rapid and accurate diagnosis is important for early treatment for reducing the duration
of infection as well as for preventing further potential health complications. In this work, we have
developed a novel colorimetric molecular assay that integrates nucleic acid analysis by dynamic
chemistry (ChemNAT) with reverse dot-blot hybridization in an array format for a rapid and easy
discrimination of Leishmania major and Trypanosoma cruzi. The assay consists of a singleplex PCR
step that amplifies a highly homologous DNA sequence which encodes for the RNA component of the
large ribosome subunit. The amplicons of the two different parasites differ between them by single
nucleotide variations, known as “Single Nucleotide Fingerprint” (SNF) markers. The SNF markers can
be easily identified by naked eye using a novel micro Spin-Tube device "Spin-Tube", as each of them
creates a specific spot pattern. Moreover, the direct use of ribosomal RNA without requiring the PCR
pre-amplification step is also feasible, further increasing the simplicity of the assay. The molecular
assay delivers sensitivity capable of identifying up to 8.7 copies per μL with single mismatch specificity.
The Spin-Tube thus represents an innovative solution providing benefits in terms of time, cost, and
simplicity, all of which are crucial for the diagnosis of infectious disease in developing countries.This research work has received funding from Junta de Andalucía, Consejería de Economía e Innovación (project
number 2012-BIO1778), the Spanish Ministerio de Economía y Competitividad (Grants CTQ2012-34778,
BIO2016-80519-R, FPI Grant BES-2013- 063020). This research was partially supported by the 7th European
Community Framework Program (FP7-PEOPLE-2012-CIG-Project Number 322276)
Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy
Hemoglobin H disease classification by isoelectric focusing: Molecular verification of 110 cases from Thailand
10.1373/clinchem.2004.044396Clinical Chemistry513641-644CLCH
Experience with continuous infusion of recombinant activated factor VII in the Asia-Pacific region
SERUM FERRITIN FOR PREDICTING CLINICALLY RELEVANT LIC THRESHOLDS TO GUIDE MANAGEMENT OF PATIENTS WITH NONTRANSFUSION-DEPENDENT THALASSEMIA TREATED WITH DEFERASIROX: THALASSA STUDY EXTENSION ANALYSIS
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
Objective: Patients with non-transfusion-dependent thalassemia (NTDT) often develop iron overload and related complications, and may require iron chelation. However, the risk of over-chelation emerges as patients reach low, near-normal body iron levels and dose adjustments may be needed. In the THALASSA study, the threshold for chelation interruption was LIC <3 mg Fe/g dw (LIC<3); 24 patients receiving deferasirox for up to 2 yr reached this target. A post hoc analysis was performed to characterize the safety profile of deferasirox as these patients approached LIC<3. Methods: THALASSA was a randomized, double-blind, placebo-controlled study of two deferasirox regimens (5 and 10 mg/kg/d) versus placebo in patients with NTDT. Patients randomized to deferasirox or placebo in the core could enter a 1-yr extension, with all patients receiving deferasirox (extension starting doses based on LIC at end-of-core and prior chelation response). The deferasirox safety profile was assessed between baseline and 6 months before reaching LIC<3 (Period 1), and the 6 months immediately before achieving LIC<3 (Period 2). Results: Mean ± SD deferasirox treatment duration up to reaching LIC<3 was 476 ± 207 d, and deferasirox dose was 9.7 ± 3.0 mg/kg/d. The exposure-adjusted AE incidence regardless of causality was similar in periods 1 (1.026) and 2 (1.012). There were no clinically relevant differences in renal and hepatic laboratory parameters measured close to the time of LIC<3 compared with measurements near the previous LIC assessment. Conclusions: The deferasirox safety profile remained consistent as patients approached the chelation interruption target, indicating that, with appropriate monitoring and dose adjustments in relation to iron load, low iron burdens may be reached with deferasirox with minimal risk of over-chelation